Consolidated Statement Of Income

Fuso Pharmaceutical Industries,Ltd. - Filing #7299997

Concept 2024-04-01 to
2024-09-30
2023-04-01 to
2023-09-30
Consolidated statement of income
Statement of income
Net sales
29,739,000,000 JPY
27,424,000,000 JPY
Operating expenses
Operating expenses - general
Depreciation
158,000,000 JPY
153,000,000 JPY
Cost of sales
21,356,000,000 JPY
20,547,000,000 JPY
Operating expenses
Selling, general and administrative expenses
5,947,000,000 JPY
5,777,000,000 JPY
Operating expenses
Gross profit (loss)
8,382,000,000 JPY
6,876,000,000 JPY
Ordinary profit (loss)
2,143,000,000 JPY
1,098,000,000 JPY
Operating expenses
Research and development expenses
714,000,000 JPY
637,000,000 JPY
Net sales
Operating profit (loss)
2,434,000,000 JPY
1,099,000,000 JPY
General and administrative expenses
Cost of sales
Selling, general and administrative expenses
Salaries
1,166,000,000 JPY
1,207,000,000 JPY
Non-operating income
Other
21,000,000 JPY
30,000,000 JPY
Non-operating income
156,000,000 JPY
161,000,000 JPY
Extraordinary income
JPY
39,000,000 JPY
Extraordinary losses
7,000,000 JPY
112,000,000 JPY
Non-operating expenses
Interest expenses
72,000,000 JPY
81,000,000 JPY
Other
24,000,000 JPY
31,000,000 JPY
Non-operating expenses
447,000,000 JPY
162,000,000 JPY
Gross profit
Profit (loss) before income taxes
2,136,000,000 JPY
1,025,000,000 JPY
Extraordinary income
Gain on sale of investment securities
JPY
39,000,000 JPY
Income taxes - current
576,000,000 JPY
291,000,000 JPY
Extraordinary losses
Loss on retirement of non-current assets
7,000,000 JPY
11,000,000 JPY
Income taxes - deferred
24,000,000 JPY
17,000,000 JPY
Income taxes
600,000,000 JPY
308,000,000 JPY
Profit (loss)
1,535,000,000 JPY
717,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.